TEM stock rallies 7.3% after the FDA clears its second cardiology AI tool, witnessing a 48% surge in just three months.

Tempus AI said it will work with AstraZeneca and Pathos AI to build a multimodal foundation model in oncology that can gather biological and clinical insights, discover novel drug targets and ...

Tempus AI Inc (NASDAQ: TEM) came ... Spruce Point cited several reasons, including account irregularities and eroding ties with key clients like AstraZeneca, for its bet against the Nasdaq listed ...

Tempus AI recently announced a landmark three-year, $200 million data and modeling license agreement with AstraZeneca AZN and Pathos to develop the world’s largest oncology-focused foundation model.

Amid a bullish backdrop for the broader market, Tempus AI (NASDAQ: TEM) stock is posting big gains Wednesday. The company's share price was up 15.8% as of 1:45 p.m. ET. At the same point in time ...

However, a deal like the AstraZeneca and Pathos AI agreements is expensive, and so Tempus will have to work to turn excitement from other pharmaceutical companies into "tangible projects," he said.

Tempus AI reports first-quarter revenue of $255.74 million, beating estimates of $248.13 million. ... Tempus AI highlighted multi-year strategic collaborations with AstraZeneca and Pathos, ...

Tempus AI, AstraZeneca, iRhythm Technologies and SOPHiA GENETICS are included in this Analyst Blog. ... Tempus AI has skyrocketed 21% in the last three days, ...

Amid a bullish backdrop for the broader market, Tempus AI (NASDAQ: TEM) stock is posting big gains Wednesday. At the same point in time, the S&P 500 was up 2.1%, and the Nasdaq Composite had risen ...